Production (Stage)
Revelation Biosciences, Inc.
REVB
$2.97
$0.103.48%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 4.48M | 4.43M | 4.54M | 4.70M | 4.60M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 8.17M | 7.98M | 8.55M | 9.53M | 8.94M |
| Operating Income | -8.17M | -7.98M | -8.55M | -9.53M | -8.94M |
| Income Before Tax | -14.41M | -15.04M | -15.52M | -15.90M | -8.96M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -14.41 | -15.04 | -15.52 | -15.90 | -8.96 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -14.41M | -15.04M | -15.52M | -15.90M | -8.96M |
| EBIT | -8.17M | -7.98M | -8.55M | -9.53M | -8.94M |
| EBITDA | -8.14M | -7.95M | -8.52M | -9.50M | -8.91M |
| EPS Basic | -307.70 | -419.46 | -404.52 | -364.37 | -118.10 |
| Normalized Basic EPS | -192.31 | -262.16 | -252.83 | -227.73 | -73.81 |
| EPS Diluted | -307.87 | -419.63 | -404.69 | -364.37 | -118.10 |
| Normalized Diluted EPS | -192.31 | -262.16 | -252.83 | -227.73 | -73.81 |
| Average Basic Shares Outstanding | 529.20K | 228.10K | 112.60K | 56.80K | 22.70K |
| Average Diluted Shares Outstanding | 529.20K | 228.10K | 112.60K | 56.80K | 22.70K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |